Print Page | Sign In | Join Today
News & Press: Company News

AmpliPhi Biosciences Announces $18 Million Private Placement

Thursday, December 19, 2013  
Share |
AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that it has entered into a definitive stock purchase agreement to raise approximately $18 million in a private placement financing.

AmpliPhi BioSciences Corporation is a biotechnology company focused on the development and commercialization of novel bacteriophage-based therapeutics. The Company's product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi was created in 2011 through the merger of BioControl Ltd with Targeted Genetics Inc. and subsequent combination with Special Phage Services in 2012. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation [NYSE: XON], the U.S. Army and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies. The Company is US-headquartered in Richmond, Virginia and has operations in Colworth, UK and Sydney, Australia.

Our Sponsors

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected